Podcast

Diabetes Dialogue: Sit Down with Diabetes Care and Education Specialist of the Year, Anastasia Albanese-O'Neill, PhD

Among the most coveted honors among those in the diabetes community is the Association of Diabetes Care and Education Specialists (ADCES) award for the diabetes care and education specialist of the year. An award granted to recipients as an honor for special contortions to the field of diabetes management through dedication, innovation, and sensitivity to patient care, the 2022 awardee is Anastasia Albanese-O’Neill, PhD, director of community screening and clinical trials education at the Juvenile Diabetes Research Foundation (JDRF).

An individual who found unexpectedly found her way to the diabetes community as a result of personal connection, O’Neill joined the field later than many of her colleagues, but her time in the field has been characterized by her fervor to advance care of patients with type 1 diabetes. Ahead of the ADCES 2022 annual meeting, the hosts of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, Diana Isaacs, PharmD, and Natalie Bellini, DNP, reached out to O’Neill to take part in an interview about what inspires her passion, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

That conversation is the subject of the special edition ADCES 22 episode of Diabetes Dialogue found below:

Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on Spotify and Apple Podcasts.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.